Treatment with anti-tumor necrosis factor biologic agents in human T lymphotropic virus type I-positive patients with rheumatoid arthritis

Arthritis Care and Research

Volumn 66, Issue 5, 2014, Pages 788-792

  Umekita, Kunihiko ^a,c   Hidaka, Toshihiko ^b   Miyauchi, Shunichi ^a   Ueno, Shiro ^a   Kubo, Kazuyoshi ^a   Takajo, Ichiro ^a   Hashiba, Yayoi ^b   Kai, Yasufumi ^b   Nagatomo, Yasuhiro ^a   Okayama, Akihiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Zenjinkai Shimin No Mori Hospital   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; T CELL LEUKEMIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899063386     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22205     Document Type: Article

References (15)

1. Moot RJ, Naisbett-Groet B,. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012; 51: 2252-61.
2. Satake M, Yamaguchi K, Tadokoro K,. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012; 84: 327-35.
3. Watanabe T,. HTLV-1 associated diseases. Int J Hematol 1997; 66: 257-78.
4. Nishioka K, Sumida T, Hasunuma T,. Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Arthritis Rheum 1996; 39: 1410-8. (Pubitemid 26270103)
5. Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S,. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 463-6. (Pubitemid 26085222)
6. Sato K, Maruyama I, Maruyama Y, Kitajima I, Nakajima Y, Higaki M, et al. Arthritis in patients infected with human T lymphotropic virus type I: clinical and immunopathologic features. Arthritis Rheum 1991; 34: 714-21.
7. Umekita K, Umeki K, Miyauchi S, Ueno S, Kusumoto N, Kubo K, et al. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series. Mod Rheumatol 2013. E-pub ahead of print.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
9. Mori N, Shirakawa F, Shimizu H, Murakami S, Oda S, Yamamoto K, et al. Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of NF-κ B. Blood 1994; 84: 2904-11. (Pubitemid 24328077)
10. Mori N, Shirakawa F, Abe M, Kamo Y, Koyama Y, Murakami S, et al. Human T-cell leukemia virus type I tax transactivates the interleukin-6 gene in human rheumatoid synovial cells. J Rheumatol 1995; 22: 2049-54.
11. Yoshihara Y, Tsukazaki T, Osaki M, Nakashima M, Hasui K, Shindo H,. Altered expression of inflammatory cytokines in primary osteoarthritis by human T lymphotropic virus type I retrovirus infection: a cross-sectional study. Arthritis Res Ther 2004; 6: R347-54.
12. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008; 18: 146-52.
13. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 2010; 20: 531-8.
14. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol 2011; 38: 1585-92.
15. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007; 17: 28-32. (Pubitemid 46455693)